What is Maxygen?
Headquartered in the San Francisco Bay Area, Maxygen operates at the intersection of synthetic biology and industrial biotechnology. The company is a pioneer in directed evolution, a methodology that mimics natural selection to optimize proteins and enzymes for specific industrial and therapeutic applications. By leveraging its sophisticated molecular breeding technology, Maxygen generates vast libraries of genetic diversity, enabling partners to accelerate product development cycles. Their service-oriented model, which includes advanced DNA synthesis and cloning, allows clients to maintain intellectual property control while benefiting from Maxygen's technical expertise in protein function enhancement. This strategic positioning makes them an essential service provider for firms seeking to improve the efficacy and stability of biological products.
How much funding has Maxygen raised?
Maxygen has raised a total of $96K across 1 funding round:
Debt
$96K
Debt (2021): $96K with participation from PPP
Key Investors in Maxygen
PPP
Public-Private Partnership
What's next for Maxygen?
With the infusion of this recent capital, Maxygen is well-positioned to scale its operational capacity and deepen its research into next-generation protein engineering. The company's strategic roadmap likely involves expanding its library screening throughput and enhancing its proprietary molecular biology toolkits to meet the growing demand for sustainable, bio-based solutions. As the biotech industry shifts toward more precise genetic manipulation, Maxygen's ability to provide cost-effective, high-content screening services will be critical. Future growth will likely focus on diversifying its partner base and integrating more automated workflows to maintain its competitive edge in the rapidly evolving landscape of molecular innovation.
See full Maxygen company page
